Cargando…

Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis

Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood monon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wandinger, Klaus-Peter, Wessel, Karl, Neustock, Petra, Siekhaus, Aja, Kirchner, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science B.V. 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127026/
https://www.ncbi.nlm.nih.gov/pubmed/9168171
http://dx.doi.org/10.1016/S0022-510X(97)05383-5
_version_ 1783516271912943616
author Wandinger, Klaus-Peter
Wessel, Karl
Neustock, Petra
Siekhaus, Aja
Kirchner, Holger
author_facet Wandinger, Klaus-Peter
Wessel, Karl
Neustock, Petra
Siekhaus, Aja
Kirchner, Holger
author_sort Wandinger, Klaus-Peter
collection PubMed
description Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood mononuclear cells (PBMC) in 21 consecutive patients with clinically definite MS to produce interferons and lymphokines in response to viral or mitogenic stimulation. Ten patients showed clinical signs of disease activity (acute relapse) and 11 patients were in a stable condition. Additionally, white blood count, leukocyte differentiation and lymphocyte subtyping were performed. A group of age-related healthy blood donors served as control (n=20). There was no difference between patients and controls in the production of IFN-γ, tumor necrosis factor (TNF)-α and soluble interleukin (IL)-2 receptor. IFN-α and IFN-β responsiveness, however, was significantly lower in patients with stable disease than in patients with active disease and controls (p<0.001). Furthermore, secretion of IL-2 after stimulation was significantly diminished in both patient groups as compared to the control group (p<0.01). Analysis of T-cell subsets revealed a significantly lower amount of CD8(+) T-cells in patients with stable disease, leading to a significantly higher CD4/CD8 ratio in this group as compared to patients with active disease. Our study depicted an IL-2 deficiency in MS patients which is shared with other autoimmune diseases. In addition, our findings suggest that the ability to produce type-I IFNs, IFN-α and IFN-β, is primarily impaired in MS patients and changes in correlation to the course of disease activity.
format Online
Article
Text
id pubmed-7127026
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Elsevier Science B.V.
record_format MEDLINE/PubMed
spelling pubmed-71270262020-04-08 Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis Wandinger, Klaus-Peter Wessel, Karl Neustock, Petra Siekhaus, Aja Kirchner, Holger J Neurol Sci Article Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood mononuclear cells (PBMC) in 21 consecutive patients with clinically definite MS to produce interferons and lymphokines in response to viral or mitogenic stimulation. Ten patients showed clinical signs of disease activity (acute relapse) and 11 patients were in a stable condition. Additionally, white blood count, leukocyte differentiation and lymphocyte subtyping were performed. A group of age-related healthy blood donors served as control (n=20). There was no difference between patients and controls in the production of IFN-γ, tumor necrosis factor (TNF)-α and soluble interleukin (IL)-2 receptor. IFN-α and IFN-β responsiveness, however, was significantly lower in patients with stable disease than in patients with active disease and controls (p<0.001). Furthermore, secretion of IL-2 after stimulation was significantly diminished in both patient groups as compared to the control group (p<0.01). Analysis of T-cell subsets revealed a significantly lower amount of CD8(+) T-cells in patients with stable disease, leading to a significantly higher CD4/CD8 ratio in this group as compared to patients with active disease. Our study depicted an IL-2 deficiency in MS patients which is shared with other autoimmune diseases. In addition, our findings suggest that the ability to produce type-I IFNs, IFN-α and IFN-β, is primarily impaired in MS patients and changes in correlation to the course of disease activity. Elsevier Science B.V. 1997-07-01 2000-03-15 /pmc/articles/PMC7127026/ /pubmed/9168171 http://dx.doi.org/10.1016/S0022-510X(97)05383-5 Text en Copyright © 1997 Elsevier Science B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Wandinger, Klaus-Peter
Wessel, Karl
Neustock, Petra
Siekhaus, Aja
Kirchner, Holger
Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title_full Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title_fullStr Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title_full_unstemmed Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title_short Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
title_sort diminished production of type-i interferons and interleukin-2 in patients with multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127026/
https://www.ncbi.nlm.nih.gov/pubmed/9168171
http://dx.doi.org/10.1016/S0022-510X(97)05383-5
work_keys_str_mv AT wandingerklauspeter diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis
AT wesselkarl diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis
AT neustockpetra diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis
AT siekhausaja diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis
AT kirchnerholger diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis